The HTX-011 Story

HTX-011 Breakthrough in Pain Management

ZYNRELEF, the commercial name for HTX-011, is the first and only FDA-approved extended-release dual-acting local anesthetic. ZYNRELEF has been clinically proven to manage pain and eliminate the need for opioids for up to 72 hours following surgery. This surpasses the performance o f bupivacaine, the current standard-of-care.

Achieving lasting effectiveness with local anesthetics beyond 12–24 hours is challenging due to surgery-induced inflammation reducing anesthetic penetration. HTX-011 combines bupivacaine and low-dose meloxicam to address this issue.  Preclinical studies using MD Biosciences' post-operative pain models in pig were conducted to confirm HTX-011's mechanism of action. Continue reading here.

See how you can also benefit from our models. 

Access Webinar

Pre-clinical incision model: Extended released formulation of bupivacaine and meloxicam combination resulted in a better effect then either bupivacaine or meloxicam alone.

This could be you!

MD Biosciences has expertise in pain, neurodegeneration and neuroinflammation bringing insight and methods that increase value and clinical translatability. If you would like to learn more about our models, feel free to contact us. 

References:

¹Mechanism of action of HTX-011: a novel, extended-release, dual-acting local anesthetic formulation for postoperative pain. Ottoboni T, Quart B, Pawasauskas J, Dasta JF, Pollak RA, Viscusi ER.  Reg Anesth Pain Med. Dec 2019